Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Royalty Pharma

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804

Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D…

by Timos Papagatsias

Immunology

Immunology Video Recap—January 14, 2026

This Immunology video highlights major regulatory approvals, late-stage…

Immunology

Immunology Today—January 14, 2026

This week's Immunology update highlights key advances including late-stage…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas
Cardiovascular Today—April 16, 2026
Rare Diseases Today—April 16, 2026
Cell and Gene Therapy Today—April 16, 2026
Vaccines Today—April 10, 2026

Tags

AI-Driven Healthcare Amazon Pharmacy Aurobindo Pharma Bain Capital Caribou Biosciences chronic disease CMT SORD Cosentyx Elsunersen Endocrinology News Fondazione Telethon FOR46 George Institute for Global Health Guardian 4 Hetero imlunestrant Ischemic Heart Failure With Reduced Ejection Fraction Isturisa KMT2A lenacapavir life sciences software lyr-100 MFDS Korea model ops molecular glues Neladalkib Neurofibromatosis Type 1 NGLY1 Deficiency Nintedanib Paltusotine Pediatric psoriasis Primary hyperparathyroidism PRISM AI radiology ProStyle M Quiver Bioscience ruxolitinib Severe Acquired Aplastic Anemia Sirius Therapeutics Spevatamig Starlight Therapeutics STENOVA Tetralogy of Fallot TRIBE V2 vorasidenib Zenas BioPharma

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas
Cardiovascular Today—April 16, 2026
Rare Diseases Today—April 16, 2026
Cell and Gene Therapy Today—April 16, 2026
Vaccines Today—April 10, 2026

TAGS

AI-Driven Healthcare Amazon Pharmacy Aurobindo Pharma Bain Capital Caribou Biosciences chronic disease CMT SORD Cosentyx Elsunersen Endocrinology News Fondazione Telethon FOR46 George Institute for Global Health Guardian 4 Hetero imlunestrant Ischemic Heart Failure With Reduced Ejection Fraction Isturisa KMT2A lenacapavir life sciences software lyr-100 MFDS Korea model ops molecular glues Neladalkib Neurofibromatosis Type 1 NGLY1 Deficiency Nintedanib Paltusotine Pediatric psoriasis Primary hyperparathyroidism PRISM AI radiology ProStyle M Quiver Bioscience ruxolitinib Severe Acquired Aplastic Anemia Sirius Therapeutics Spevatamig Starlight Therapeutics STENOVA Tetralogy of Fallot TRIBE V2 vorasidenib Zenas BioPharma

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy